(19)
(11) EP 4 476 212 A1

(12)

(43) Date of publication:
18.12.2024 Bulletin 2024/51

(21) Application number: 23705679.1

(22) Date of filing: 10.02.2023
(51) International Patent Classification (IPC): 
C07D 405/14(2006.01)
A61P 3/00(2006.01)
A61P 3/06(2006.01)
A61P 1/00(2006.01)
A61P 9/00(2006.01)
A61P 9/06(2006.01)
A61P 9/12(2006.01)
A61P 25/02(2006.01)
A61K 31/4439(2006.01)
A61P 3/04(2006.01)
A61P 3/10(2006.01)
A61P 1/16(2006.01)
A61P 9/04(2006.01)
A61P 9/10(2006.01)
A61P 25/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 405/14; A61P 3/00; A61P 3/04; A61P 3/06; A61P 3/10; A61P 1/00; A61P 1/16; A61P 9/00; A61P 9/04; A61P 9/06; A61P 9/10; A61P 9/12; A61P 25/00; A61P 25/02
(86) International application number:
PCT/IB2023/051207
(87) International publication number:
WO 2023/152698 (17.08.2023 Gazette 2023/33)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 10.02.2022 US 202263308843 P
24.03.2022 US 202263323401 P
11.04.2022 WO PCT/IB2022/053367
07.10.2022 US 202263378749 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • ALLAN, Martin
    Cambridge, Massachusetts 02139 (US)
  • CARSON, Matthew
    Cambridge, Massachusetts 02139 (US)
  • CAYA, Thomas
    Cambridge, Massachusetts 02139 (US)
  • FAZAL, Tanzina
    Cambridge, Massachusetts 02139 (US)
  • SMITH, Troy
    Cambridge, Massachusetts 02139 (US)
  • SU, Liansheng
    Cambridge, Massachusetts 02139 (US)
  • YANG, Lihua
    Cambridge, Massachusetts 02139 (US)
  • ZHANG, Ping
    Cambridge, Massachusetts 02139 (US)
  • QIAN, Ming
    Cambridge, Massachusetts 02139 (US)

(74) Representative: Amodio, Eliana Lucia 
Novartis Pharma AG Patent Department Lichtstrasse 35
4056 Basel
4056 Basel (CH)

   


(54) 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY